Trials / Completed
CompletedNCT05704725
A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)
An Open Label, Two-Arm Study in Subjects With Chorioretinal Vascular Disease to Evaluate ABP 938 and Aflibercept (Eylea®) in a Prefilled Syringe
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to is to assess the ability of retina specialists to successfully administer, via an intravitreal (IVT) injection, a 2 mg dose of ABP 938, using the ABP 938 aflibercept prefilled syringe (PFS), compared to a 2 mg dose of aflibercept using the aflibercept PFS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABP 938 | IVT injection |
| DRUG | Aflibercept | IVT injection |
Timeline
- Start date
- 2023-01-23
- Primary completion
- 2023-02-17
- Completion
- 2023-03-24
- First posted
- 2023-01-30
- Last updated
- 2025-02-14
- Results posted
- 2025-02-14
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05704725. Inclusion in this directory is not an endorsement.